Onyx Pharmaceuticals and Bayer HealthCare have restructured their partnership for the global development and marketing of Nexavar (sorafenib) tablets, and entered into a new agreement for Bayer’s regorafenib, a late-stage oncology compound.   Bayer will have the final say for global development and commercialization of regorafenib and Onyx will receive a royalty on any future global sales in oncology. Both companies will promote regorafenib in the U.S.   Under the revised Nexavar collaboration,...